Brief: Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates For Its Covid-19 Oral Drug Program

Cocrystal Pharma

27/01/2022 13:19

Jan 27 (Reuters) - Cocrystal Pharma Inc  COCP.O :
    * COCRYSTAL PHARMA SELECTS TWO LEAD ANTIVIRAL DRUG
CANDIDATES FOR
ITS COVID-19 ORAL DRUG PROGRAM
    * COCRYSTAL PHARMA - CLINICAL TRIALS WITH ORAL PROGRAM,
CDI-45204
INHALATION/PULMONARY-DELIVERED COVID-19 ANTIVIRAL CANDIDATES
EXPECTED TO BEGIN IN 2022
    * COCRYSTAL PHARMA INC - PLANS TO INITIATE A FIRST-IN-HUMAN
TRIAL
WITH ONE SELECTED CANDIDATE AS SOON AS POSSIBLE THIS YEAR
    * COCRYSTAL PHARMA - CDI-988 & CDI-873 SHOWED SUPERIOR IN
VITRO
POTENCY AGAINST SARS-COV-2 WITH ACTIVITY MAINTAINED AGAINST
VARIANTS INCLUDING OMICRON

Source text for Eikon:  ID:nGNX9ZDq1F 
Further company coverage:  COCP.O 

 ((Reuters.Briefs@thomsonreuters.com;))